Allergy

An updated epidemiological review paints a concerning picture of pediatric cow’s milk allergy in the US.

Long-term lung inflammation associated with allergen exposure is linked to the development of anxiety later in adulthood, according to a new study.

The FDA has accepted Sanofi’s supplemental biologics license application (sBLA) for priority review of dupilumab (Dupixent) in patients aged 12 to 17 years with moderate-to-severe atopic dermatitis.

Allergic rhinitis involves the immune system, which responds to allergens by releasing histamine, causing inflammatory symptoms in the nose, throat, and eyes—which can also worsen asthma conditions.

Why delving into the symptoms of the most at-need patients is critical for care.

The FDA has approved a 0.15mg dosage of Symjepi, an epinephrine injection, for the emergency treatment of serious allergic reactions in children.

The patient population tends to have a more unbalanced immune profile to that of European American patients, indicating a potential for tailored treatment options to combat inflammation.

Investigators find more evidence to support IgE as a reliable biomarker for targeted biologic therapy in asthma management.

In prior studies, younger populations that have asthma were not found to be impacted by autonomy preferences.

IgE for alpha-gal was identified in 26% of the patients, and plaque buildup was 30% higher in those patients compared to those that were not sensitized.

The rare condition affects 30,000-40,000 US patients annually. Rituximab becomes its first indicated biologic treatment.